Search

Displaying results 3411 - 3420 of 10000 in total
  1. Drug

    Butabarbital

    go.drugbank.com/drugs/DB00237
    ApprovedIllicitWithdrawn

    [A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.[L13613] … [A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines.

  2. Drug

    Kappadione

    go.drugbank.com/drugs/DB09332
    Approved

    It has been found to have carcinogenic potential in mammalian cells as well as cytotoxic properties [L1544]. … Studies involving the active metabolite of this formulation, menadione, showed oocyte toxicity in a study of mice [L1544].

  3. Drug

    Pegamotecan

    go.drugbank.com/drugs/DB12842
    Investigational

    Pegamotecan has been used in trials studying the treatment of Cancer of Stomach, Sarcoma, Soft Tissue, and Gastroesophageal Cancer.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Deoxyspergualin

    go.drugbank.com/drugs/DB12991
    Investigational

    Deoxyspergualin has been used in trials studying the treatment of Lupus Nephritis, Chronic Rejection, and Diabetes Mellitus, Type 1.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Sulfabenzamide

    go.drugbank.com/drugs/DB09355
    ApprovedWithdrawn

    Sulfabenzamide is an antimicrobial agent often used in conjunction with sulfathiazole and sulfacetamide as a topical intravaginal antibacterial preparation.

    Synonyms: N-Benzoylsulfanilamide, N-Sulfanilylbenzamide
  6. Drug

    DDP733

    go.drugbank.com/drugs/DB05049
    Investigational

    Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. … DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD).

  7. Drug

    Trodusquemine

    go.drugbank.com/drugs/DB06333
    Investigational

    It has demonstrated the ability to stimulate regeneration of heart and multiple other tissues in animal models [A176600].

  8. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure

  9. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.

  10. Drug

    Micronomicin

    go.drugbank.com/drugs/DB13274
    Approved

    Micronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names Sagamicin and Luxomicina.